A Women’s Health and Wellness Company - Jefferies Group › CMSFiles › Jefferies.com › files...
Transcript of A Women’s Health and Wellness Company - Jefferies Group › CMSFiles › Jefferies.com › files...
© 2017 Viveve, Inc. Confidential and Proprietary.0
Advancing the Science of Satisfaction
A Women’s Health and Wellness Company
Corporate Presentation(NASDAQ: VIVE)
© 2017 Viveve, Inc. Confidential and Proprietary.1
Safe Harbor Statement
All statements in this presentation that are not based on historical fact are “forward looking statements”.While management has based any forward looking statements included in this release on its currentexpectations, the information on which such expectations were based may change. These forward lookingstatements rely on a number of assumptions concerning future events and are subject to a number of risks,uncertainties and other factors, many of which are outside of our control, which could cause actual resultsto materially differ from such statements.
Such risks, uncertainties, and other factors include, but are not limited to: (i) we currently do not have theability to market our system in the U.S.; (ii) we will need to obtain FDA clearance or approval, which maynot be granted; (iii) our business is not profitable, and we may not be able to achieve profitability; (iv) wedepend on distributors to market and sell our products and they may not be successful; (v) we currentlyhave limited sales and marketing resources; (vi) the fluctuation of global economic conditions; (vii) theperformance of management and our employees; (viii) our ability to obtain financing; (ix) competition andgeneral economic conditions; and (x) other factors that are to be detailed in our periodic and currentreports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidlychanging environment where new and unanticipated risks may arise. Accordingly, investors should notplace any reliance on forward-looking statements as a prediction of actual results. We disclaim anyintention to, and undertake no obligation to, update or revise forward-looking statements.
.
© 2017 Viveve, Inc. Confidential and Proprietary.2
A women’s health and wellness company commercializing a clinically proven cryogen-cooled monopolar radiofrequency (CMRF)
technology that generates new collagen and restores tissue
The GENEVEVE™ Treatment is indicated for the treatment of vaginal laxity or improvement of sexual function in 51
countries around the world*
* In the United States the Viveve System is indicated for general surgical procedures for electrocoagulation and hemostasis
© 2017 Viveve, Inc. Confidential and Proprietary.3
Company Highlights
• Completed largest clinical trial for vaginal laxity and sexual function ever conducted – JSM publication
• Pending IDE for sexual function label expansion – Data expected 2H 2018
• Q4 2016 FDA Clearance – general indication
• Regulatory approval/indications to sell in 54 countries
• Vaginal laxity/sexual function indication in 51 countries
• Over $7M in first full year of sales
• Double digit sales growth seven consecutive quarters
• 2017 revenue guidance: $14M – $16M
Rapid Commercial
Growth
Demonstrated Clinical
Evidence
Significant Regulatory Momentum
© 2017 Viveve, Inc. Confidential and Proprietary.4
Experienced Leadership Team
Patricia Scheller Chief Executive Officer
> 25 / 5
Scott Durbin Chief Financial Officer
> 20 / 4
James Atkinson President andChief Business Officer
> 30 / 2
Daniel Janney Debora Jorn Jon Plexico Arlene Morris Lori Bush
Managing Director, Alta Partners
Former EVP and Company Chair, Valeant
Founder and Managing Member, Stonepine Capital
Former President and CEO of SyndaxPharmaceuticals
Former President and CEO, Rodan + Fields
Key Management & Previous Experience
Independent Board of Directors
Years Experience: Industry / Viveve
MEDICALSTIMULATIONCORPORATION
© 2017 Viveve, Inc. Confidential and Proprietary.5
Significant Unmet Need
• Vaginal childbirth overstretches the vaginal introitus (opening)
Feeling of “Looseness”
Diminished sensation during intercourse
Reduction in sexual function and quality of life
Vaginal Laxity - a significant concern for millions of women
Data sources - available upon request.
Impacts ~50% of Women Post-Partum
#1 Reported ChangePost-Partum
• UroGYNs recognize it is underreported, yet bothersome, medical condition that impacts personal happiness and sexual function
• Vaginal laxity causes include: pregnancy, childbirth, aging, genetic predisposition, lifestyle, and/or trauma
© 2017 Viveve, Inc. Confidential and Proprietary.6
Enormous Global Market Opportunity
Significant Additional Market Opportunities
• Stress Incontinence• Vaginal Atrophy• External applications
$7 Billion Consumable Post-Partum Market
EXCLUDES:
• Equipment sales
• Repeat procedures
• Additional indications
13 Million Women
Worldwide Potential
Early Adopters
• 3 million in US• 10 million OUS
$
© 2017 Viveve, Inc. Confidential and Proprietary.7
Vaginal Rejuvenation – Competitive Landscape
Treatment Paradigm
GENEVEVE™ Coolant (CMRF) allows depth of penetration
while maintaining patient comfort & safety
Reproducible procedure
Demonstrated large scale clinical evidence
Significant patent coverage
Pelvic floor exercises (Kegels)
Highly invasive, costly, painful and lengthy recovery yet nearly 115,000 annual procedures worldwide
BehavioralModifications
Energy-basedDevices
SurgicalIntervention
© 2017 Viveve, Inc. Confidential and Proprietary.8
The Viveve Solution
Viveve® System utilizes internationally patented,
cryogen-cooled monopolar RF energy (CMRF) technology
2Physician operated table-top device
Single-use consumable treatment tip
1
© 2017 Viveve, Inc. Confidential and Proprietary.9
The GENEVEVE Treatment
• Treatment tip delivers pulses to the tissue
• Each pulse lasts ~8 seconds
• Total procedures consists of ~110 pulses
• Total procedure lasts only 30 minutes
Only clinically proven and effective, non-surgical procedure
for vaginal tissue*
* Journal of Sexual Medicine 2017;14:215-225. In the United States the Viveve System is indicated for general surgical procedures for electrocoagulation and hemostasis.
Treatment Technique
© 2017 Viveve, Inc. Confidential and Proprietary.10
Physician and Patient Benefits
• Clinically proven to improve sexual function
• 30 minute comfortable in-office procedure
• No anesthesia; non-ablative and non-surgical
• Little or no downtime / recovery period
• Lasting results up to 12 months
• Significant in-office revenue
55% of surveyed women agreed “this vaginal tightening
procedure is for me”
84% of surveyed physicians interested in performing the procedure
Data sources - available upon request.
“It works! Sex is enjoyable and satisfying again – for me and my
husband!”
“The sensation just kept getting better months following the
treatment. It lasts!”
© 2017 Viveve, Inc. Confidential and Proprietary.11
Successful Results in Multiple Trials
Data sources - available upon request.
Demonstrated scientific rigor establishing efficacy and safety
CMRF Technology based on proven Thermage technology
Animal Studies: Documented fibroblast activation, collagen remodeling, no cellular or tissue damage
VIVEVE II IDE approval pending
Multi-center, double-blind, sham controlled study to improve sexual function at 12 months
VIVEVE I Study: Multi-center, blinded, sham-controlled trial - active treatment group 3X more likely to report NOvaginal laxity and sustained improvement in sexual function at 6 months with NO related adverse events
Continued commitment to providing clinically proven solutions
US and Japan Studies: 88% of women reported increased vaginal tightness at 12 months with NO serious adverse events
© 2017 Viveve, Inc. Confidential and Proprietary.12
VIVEVE I – Demonstrated Improvement in Sexual Function
Largest controlled study ever conducted to assess treatment of vaginal laxity
Significant and sustained
improvement after a SINGLE treatment
Adjusted Mean Difference of 3.2 at
6 Months p-value = 0.009
FSFI – Female Sexual Function Index: a validated patient reported outcome questionnaire FSFI analysis conducted on 103 per protocol patients with baseline scores less than 26.5.
© 2017 Viveve, Inc. Confidential and Proprietary.13
VIVEVE II – US Sexual Function Indication
VIveve Treatment of the Vaginal Introitus to EValuate Efficacy
• Randomized (1:1), double-blinded and sham-controlled
• Enrollment ~250 patients at up to 25 clinical sites in the U.S. and Canada
• Primary efficacy endpoint – FSFI total score at 6 months
• Secondary efficacy endpoints – Various domain scores at 6 months
• Safety and efficacy at 12 months
Sexual Function…treatment of vaginal
tissue to improve sexual function
FDA Clearance1H 2019
• Clinically proven path to approval
• IDE submission under FDA review
• VIVEVE II study start – Q4 2017
© 2017 Viveve, Inc. Confidential and Proprietary.14
Track Record of Success
Attainment of key commercial milestones at a rapid pace
Year-End 2015 Year-End 2016 Q1 2017
Reported Revenue
$1.4M $7.1M $3.04M
Installed Base 42 217 259
Distribution Coverage
46 Countries 67 Countries - 2 Direct 67 Countries – 2 Direct
Clinical Milestones
Completed VIVEVE I study
IDE submission –VIVEVE II
JSM Publication –VIVEVE I
VIVEVE II IDE reviewin process
Regulatory Approvals
20 Countries51 Countries
US, Brazil, and Korea approvals
54 CountriesKorea Expanded-
Vaginal Laxity
© 2017 Viveve, Inc. Confidential and Proprietary.15
Strong Global Commercial Footprint – 69 Countries
EUROPE29 countries
MIDDLE EAST 10 countries
ASIA PACIFIC13 countries
LATIN AMERICA15 countries
N. AMERICA2 countries
© 2017 Viveve, Inc. Confidential and Proprietary.16
International Commercialization
Extensive global distribution network
• 26 distributors covering 67 countries
• Approvals & indications to sell in 53 countries
• 4 Regional Sales Directors managing Asia Pacific, Europe, Middle East, and Latin America
Pending regulatory submissions in 14 additional countries
© 2017 Viveve, Inc. Confidential and Proprietary.17
US Commercialization
Commercial Organization:
Vice President of Sales Two Regional Directors
Twelve Territory Managers(4 Territory Managers added Q2 2017)
Physician Specialties:
Gynecologists
Urogynecologists
Plastic Surgeons
Dermatologists
P R O M O T I O N A L C A M P A I G N S
Branded Campaign
FEEL SENSATIONAL
Unbranded Campaign
Educational and empowerment initiative focused on women’s sexual health and
wellness
* In the United States the Viveve System is indicated for general surgical procedures for electrocoagulation and hemostasis
© 2017 Viveve, Inc. Confidential and Proprietary.18
Commercial Success & Rapid Adoption
Current installed base of 259 Viveve Systems globally with double digit sales growth – quarter-over-quarter – since Q3 2015
© 2017 Viveve, Inc. Confidential and Proprietary.19
2017 - Building on a Track Record of Success
• Drive GENEVEVE™ adoption
• Implement innovative education and awareness campaigns to educate and motivate
• Improve gross margins
Grow Global Revenue Commitment to Scientific Rigor An Eye to the Future
• Fund External Research Programs to explore potential new applications
• Conduct rigorous clinical trials to secure new regulatory indications
• Expand product portfolio
• Broaden indications
• Secure additional regulatory clearances